Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Infliximab in Chinese patients with active ulcerative colitis
NCT01551290Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Apr 2012
- Primary completion
- Mar 2014
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in ulcerative colitis (UC) comparing Group I: Placebo with Group II: Infliximab (2 arms). Primary endpoint: Number of participants with a clinical response at 8 weeks. Started Apr 2012; status: completed.
02
Drugs
infliximab
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT01551290.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01551290.